Latest Press Releases

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, ...

Outdated Perceptions and Practices Fuelling Mental Health Crisis, New Economist Impact Study Reveals

Â International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating barriers to vital mental health care services ...

Enhanced Conolidine: Medical Scientist Clint Winters Announces Patent Filing on CONOCB2â„¢, A Novel Conolidine Pain Relief Active Ingredient with Natural Endocannabinoids

Winters Biotechnology, led by Medical Scientist Clint Winters, has announced patent filings in relation to CONOCB2â„¢, an enhanced version of pain relieving conolidine that includes naturally occurring Endocannabinoids. This patent builds upon the ...

Jeffrey D. Horn, M.D. Announces First FDA-Approved Eye Drop to Treat Age-Related Blurry Vision Now Available at Vision for Life

Prescription drop can correct common vision problem plaguing half of the U.S. adult population NASHVILLE, Tenn. , Jan. 11, 2022 /PRNewswire/ -- Dr. Jeffrey D. Horn , M.D., medical director at Vision for Life, announced today his office is ...

BayMark Opens First Opioid Treatment Program In Kentucky

MedMark Treatment Centers Louisville is BayMark's first methadone maintenance program in Kentucky, adding a new modality of treatment to our presence. LEWISVILLE, Texas , Jan. 10, 2022 /PRNewswire-PRWeb/ --Â BayMark Health Services announced ...

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

--ASC42 is a Novel anti-viral candidate for HBV functional cure through inhibiting the transcription of HBV cccDNA into HBV RNA and reducing the HBV cccDNA stability HANGZHOU , ChinaÂ and SHAOXING, China , Jan. 10, 2022 /PRNewswire/ -- ...

Government of Canada to assist Nova Scotia with COVID-19 immunization program

OTTAWA, ON , Jan. 10, 2022 /CNW/ - The President of the Queen's Privy Council for Canada and Minister of Emergency Preparedness, the Honourable Bill Blair , confirmed that the Government of Canada has approved a Request for Federal ...

Press Releases

Premium Press Releases »

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

Outdated Perceptions and Practices Fuelling Mental Health Crisis, New Economist Impact Study Reveals

Press Releases »

Enhanced Conolidine: Medical Scientist Clint Winters Announces Patent Filing on CONOCB2â„¢, A Novel Conolidine Pain Relief Active Ingredient with Natural Endocannabinoids

Jeffrey D. Horn, M.D. Announces First FDA-Approved Eye Drop to Treat Age-Related Blurry Vision Now Available at Vision for Life

BayMark Opens First Opioid Treatment Program In Kentucky

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

Government of Canada to assist Nova Scotia with COVID-19 immunization program

Medindia Newsletters